- Trials with a EudraCT protocol (10)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
10 result(s) found for: Problem solving.
Displaying page 1 of 1.
EudraCT Number: 2008-005695-27 | Sponsor Protocol Number: 8219 | Start Date*: 2008-12-02 | |||||||||||
Sponsor Name:Eli Lilly Nederland | |||||||||||||
Full Title: Comparing Problem Solving Treatment combined with duloxetine with Problem Solving Treatment alone for patients with major depressive disorder in primary care | |||||||||||||
Medical condition: Major depressive disorder (episode or recurrent), moderately severe as principal DSM-IV diagnosis. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-005772-13 | Sponsor Protocol Number: AMISU_L_01008 | Start Date*: 2008-01-28 |
Sponsor Name:sanofi-aventis Zrt. | ||
Full Title: Comparative efficacy of amisulpride vs. risperidone on cognitive functions in patients with chronic schizophrenia. | ||
Medical condition: measure of overall cognitive functioning in chronic schizophrenia | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: HU (Completed) | ||
Trial results: View results |
EudraCT Number: 2012-004079-38 | Sponsor Protocol Number: 01112012 | Start Date*: 2013-01-14 |
Sponsor Name:Central Institute of Mental Health, Department of Psychiatry and Psychotherapy | ||
Full Title: Agomelatine treatment of major depressive episodes in the course of schizophrenic psychoses (AGOPSYCH). A single arm, prospective pilot study | ||
Medical condition: Major depressive episode | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2020-003726-23 | Sponsor Protocol Number: 1346-0013 | Start Date*: 2021-06-07 | |||||||||||
Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG | |||||||||||||
Full Title: A phase III randomized, double-blind, placebo-controlled parallel group trial to examine the efficacy and safety of iclepertin once daily over 26 week treatment period in patients with schizophreni... | |||||||||||||
Medical condition: schizophrenia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) DK (Completed) FI (Completed) CZ (Completed) BE (Completed) LT (Completed) PT (Completed) AT (Completed) BG (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-003744-84 | Sponsor Protocol Number: 1346-0012 | Start Date*: 2021-05-31 | |||||||||||
Sponsor Name:Boehringer Ingelheim RCV GmbH & Co KG | |||||||||||||
Full Title: A phase III randomized, double-blind, placebo-controlled, parallel group trial to examine the efficacy and safety of Iclepertin once daily over 26 week treatment period in patients with schizophren... | |||||||||||||
Medical condition: schizophrenia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) PL (Completed) NL (Completed) FR (Completed) SK (Completed) ES (Completed) HR (Completed) RO (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-003760-11 | Sponsor Protocol Number: 1346-0011 | Start Date*: 2021-06-08 | |||||||||||
Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG | |||||||||||||
Full Title: A phase III randomized, double-blind, placebo-controlled parallel group trial to examine the efficacy and safety of Iclepertin (BI 425809) once daily over 26 week treatment period in patients with ... | |||||||||||||
Medical condition: schizophrenia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) SE (Completed) PL (Completed) NO (Completed) IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-000499-24 | Sponsor Protocol Number: 200722 | Start Date*: 2015-02-16 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Limited | |||||||||||||
Full Title: Follow-Up Study to Assess Long-Term Safety and Outcomes in Infants and Children Born to Mothers Participating in Retosiban Treatment Studies | |||||||||||||
Medical condition: preterm labour and improve neonatal health | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) GB (Completed) ES (Completed) SE (Completed) DE (Completed) IT (Completed) FR (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-002764-27 | Sponsor Protocol Number: NILVAD2012 | Start Date*: 2013-02-04 | |||||||||||
Sponsor Name:St James's Hospital | |||||||||||||
Full Title: A European multicenre double-blind placebo controlled phase III trial of nilvadipine in mild to moderate Alzheimer's disease. | |||||||||||||
Medical condition: Mild to Moderate Alzheimer's Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) IE (Completed) SE (Completed) HU (Completed) GR (Completed) NL (Completed) IT (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-020579-21 | Sponsor Protocol Number: D1443L00082 | Start Date*: 2010-08-19 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A Phase IV Prospective, Double-blind, Double-dummy, Randomised, Crossover Study to Assess the Impact on Daily Cognitive Functioning of Quetiapine Fumarate Immediate Release (Seroquel IR®) Dosed twi... | |||||||||||||
Medical condition: Schizophrenia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) DE (Completed) ES (Completed) IT (Completed) DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-000105-53 | Sponsor Protocol Number: 17P-FU-004 | Start Date*: 2011-04-20 |
Sponsor Name:Hologic, Inc. | ||
Full Title: Estudio prospectivo, de seguimiento, de niños de 23 a 25 meses, nacidos de madres que recibieron Caproato de Hidroxiprogesterona inyectable, 250 mg/ml o vehículo, para la prevención del parto prema... | ||
Medical condition: Este es un estudio prospectivo, de seguimiento, diseñado para aportar una evaluación del desarrollo de niños nacidos de madres que participaron en el ensayo de eficacia de 17P | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | |
Trial protocol: ES (Ongoing) CZ (Completed) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
